Skip to main content

Kala Pharmaceuticals, Inc. (KALA)

NASDAQ: KALA · Delayed Price · USD
1.96
+0.06 (3.16%)
Pre-market:Oct 22, 2021 8:35 AM EDT
1.90
0.07 (3.83%)
At close: Oct 21, 4:00 PM
Market Cap119.87M
Revenue (ttm)10.78M
Net Income (ttm)-125.97M
Shares Out64.55M
EPS (ttm)-2.11
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,516,896
Open1.87
Previous Close1.83
Day's Range1.82 - 1.94
52-Week Range1.80 - 9.97
Beta0.50
AnalystsBuy
Price Target14.79 (+678.4%)
Est. Earnings DateNov 4, 2021

About KALA

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's product candidates include EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development programs co...

IndustryPharmaceuticals
IPO DateJul 20, 2017
CEOMark Iwicki
Employees188
Stock ExchangeNASDAQ
Ticker SymbolKALA
Full Company Profile

Financial Performance

In 2020, KALA's revenue was $6.36 million, an increase of 4.74% compared to the previous year's $6.07 million. Losses were -$104.33 million, 10.6% more than in 2019.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for KALA stock is "Buy." The 12-month stock price forecast is 14.79, which is an increase of 678.42% from the latest price.

Price Target
$14.79
(678.42% upside)
Analyst Consensus: Buy

News

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards ...

1 month ago - GlobeNewsWire

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in September 2021

WATERTOWN, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of...

1 month ago - GlobeNewsWire

4 Short Squeeze Penny Stocks To Watch After SPRT Stock's 1,309% Run

The SPRT stock breakout has shed light on other short-squeeze penny stocks The post 4 Short Squeeze Penny Stocks To Watch After SPRT Stock's 1,309% Run appeared first on Penny Stocks to Buy, Picks, News...

Other symbols:BBIGCLVSMMAT
1 month ago - PennyStocks

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards o...

2 months ago - GlobeNewsWire

Kala Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

-- EYSUVIS Prescriptions Increased by 93% Compared to First Quarter of 2021 -- -- Further Expanded Commercial Coverage for EYSUVIS to More Than 96 Million Lives -- -- Achieved $3.1 Million in Net Revenu...

2 months ago - GlobeNewsWire

Earnings Preview: Kala Pharmaceuticals (KALA) Q2 Earnings Expected to Decline

Kala Pharma (KALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Kala Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call

WATERTOWN, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therap...

2 months ago - GlobeNewsWire

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards o...

3 months ago - GlobeNewsWire

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Compan...

4 months ago - Business Wire

Kala Pharmaceuticals Announces EYSUVIS® Now Covered by OptumRx

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases...

4 months ago - Business Wire

Kala Pharmaceuticals to Present at Jefferies 2021 Virtual Healthcare Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...

4 months ago - Business Wire

Oxford Finance Provides $125 Million Credit Facility to Kala Pharmaceuticals

ALEXANDRIA, Va.--(BUSINESS WIRE)--Oxford Finance Provides $125 Million Credit Facility to Kala Pharmaceuticals

5 months ago - Business Wire

Kala Pharmaceuticals to Present at BofA Securities 2021 Healthcare Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...

5 months ago - Business Wire

Kala Pharmaceuticals (KALA) Reports Q1 Loss, Misses Revenue Estimates

Kala Pharma (KALA) delivered earnings and revenue surprises of 3.92% and -10.28%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Kala Pharmaceuticals: Q1 Earnings Insights

Shares of Kala Pharmaceuticals (NASDAQ:KALA) fell 0.5% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 9.26% over the past year to ($0.49), wh...

5 months ago - Benzinga

Kala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...

5 months ago - Business Wire

Kala Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...

5 months ago - Business Wire

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Compan...

7 months ago - Business Wire

Kala Pharmaceuticals Announces Preferred Position for EYSUVIS™ on Cigna

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...

7 months ago - Business Wire

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in March

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...

7 months ago - Business Wire

Kala Pharmaceuticals (KALA) Reports Q4 Loss, Lags Revenue Estimates

Kala Pharma (KALA) delivered earnings and revenue surprises of -19.57% and -6.44%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...

7 months ago - Business Wire

Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...

8 months ago - Business Wire

Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases...

8 months ago - Business Wire

Kala Pharmaceuticals (KALA) Expected to Beat Earnings Estimates: Should You Buy?

Kala Pharma (KALA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research